💰Top 10 Stock Gainers in 5 Days: PONY Leads, Which to Follow?
Hey Tigers[Allin]
During the recent 5 trading days, there are numerous stocks achieved impressive double-digit gains.
Below is a list of the top ten featuring companies with a market cap over $1 billion, daily trading volume exceeding $1 million, and gains over 20%.
Have you held any stocks that have brought you good returns? Are you familiar with these winners?
Based on the ranking table, here's a summary of the reasons for the rise and future expectations of the ten listed companies, hoping it will help you better understand them.[Miser][Heart]
A gentle reminder: Past performance is not indicative of future price increases. Analyze and plan for risks from multiple perspectives before any trade.
1. $Pony AI Inc(PONY)$ Leads with a 48% Gain
Key News and Partnerships: Pony AI showcased three new autonomous vehicle models co-developed with GAC and BAIC Motor at the Shanghai Auto Show. It has also established a partnership with tech giant Tencent, allowing users to book Pony AI's autonomous taxis via the WeChat app. Additionally, Pony AI announced a global strategic collaboration with Uber to launch autonomous taxi services in the Middle East and expand to more international markets.
Ratings and Target Price: Wall Street analysts are optimistic about its future profitability, expecting the company to achieve breakeven on a per-vehicle basis by the end of this year. The market consensus is a "Buy" rating for Pony AI, with an average target price of around $20.
2.US Telehealth Company $Hims & Hers Health Inc.(HIMS)$
Financials: The company's Q1 revenue doubled year-over-year to $586 million, a 111% increase, with a net income of $49.5 million and adjusted EBITDA of $91.1 million. It seems the controversial Super Bowl ad has paid off.
Significant Positive Events: HIMS acquired home lab testing service provider Trybe Labs during Q1 to strengthen market coverage and enhance personalized healthcare services. The company also entered into a long-term partnership with Novo Nordisk to promote its blockbuster weight loss drug Wegovy, stimulating investor interest. Additionally, Hims & Hers acquired a peptide facility in California to further strengthen its ability to provide personalized medications.
Ratings and Target Price: Morgan Stanley has a target price of $60 for HIMS with an Equal-Weight rating. Piper Sandler raised its target price from $35.00 to $39.00 while maintaining a neutral rating on the stock.
3.Beauty and Health Tech Company $ODDITY Tech Ltd.(ODD)$
Performance: Reported Q1 2025 net revenue of $268 million, a 27% year-over-year increase, with adjusted EBITDA of $52 million and net income of $38 million. The company also achieved a strong free cash flow of $87 million, with cash and investments totaling $257 million and no debt.
Guidance Upgrade: Based on the outstanding Q1 performance, Oddity raised its full-year guidance. The company expects 2025 revenue to be between $790 million and $798 million, a year-over-year increase of 22% to 23%.
Ratings and Target Price: According to MarketBeat, based on nine Wall Street analysts, the consensus rating is "Moderate Buy." Analysts have set an average target price of $54.44, with the highest target price at $66.00, indicating a potential upside of 17.46% from the current share price.
4. Autonomous Vehicle Tech Company $WeRide Inc.(WRD)$
News: NVIDIA disclosed a significant stake in WeRide for the first time, directly driving a substantial increase in the stock price. NVIDIA held about 1.74 million shares of WeRide in Q4 2024, valued at $246.5 million. WeRide and Uber announced an expanded strategic partnership to deploy autonomous robotaxis in 15 cities across Europe and the Middle East over the next five years.
Ratings and Target Price: Morgan Stanley gave WeRide Inc. (NASDAQ: WRD) an "Overweight" rating with a target price of $23.
5.Global Leader in Specialty Materials Production $ATI Inc(ATI)$
Financials: Reported Q1 2025 revenue of $1.14 billion, exceeding the expected $1.08 billion. Adjusted EPS reached $0.72, surpassing analyst expectations of $0.60. The stock price increased by 9.11%, reflecting investors' optimistic sentiment towards the company's financial report.
Ratings and Target Price: ATI maintained its full-year EPS guidance for 2025 at a robust level of $2.87-$3.09, expecting an expansion of profit margins in the second half of 2025, with the HPMC profit margin expected to exceed 24%. KeyBanc upgraded ATI's rating to "Overweight" with a target price of $55.
6.International Online Education Company $Duolingo, Inc.(DUOL)$
Financial Boost: The company released strong Q1 2025 financial results, significantly exceeding analyst expectations. Revenue reached $230 million, about 3.4% above expectations, highlighting Duolingo's strong market position and growth trajectory. The company reported EPS of $0.72, higher than the expected $0.52. After the announcement, Duolingo's stock price surged, reflecting the company's successful strategy in expanding its user base and improving operational efficiency.
Ratings and Target Price: Needham analyst Ryan MacDonald maintained Duolingo's "Buy" rating and raised the target price from $400 to $460.
7.Medical Device Company Focused on Diabetes Treatment $Tandem Diabetes Care(TNDM)$
Performance: The company's main products are insulin pumps and related diabetes management technologies. Q1 2025 reported record sales, with global GAAP sales increasing by 44% to $282.6 million, a full-year increase of 26%, totaling $940.2 million. The company expects full-year 2025 sales to be between $997 million and $1.007 billion, showing strong growth momentum.
Significant Event: Tandem Diabetes Care announced that the FDA approved its Control-IQ+ automated insulin delivery technology for type 2 diabetes patients, indicating significant progress in expanding the scope of its products.
Target Price Expectations: Based on ratings from 17 analysts, the company's average target price is $43.81, with the highest target price at $75.00 and the lowest at $20.00, indicating a potential upside of 126.84% from the current share price.
8. AI Cloud Computing Company $CoreWeave, Inc.(CRWV)$
Company Overview: CRWV went public on the Nasdaq on March 28, becoming the largest venture-backed tech IPO in the US since 2021. The company's main business is leasing NVIDIA GPU resources to other tech companies, with its largest customer being Microsoft.
Performance: CRWV signed a five-year, $11.9 billion long-term cooperation agreement with OpenAI to provide AI infrastructure support. In 2024, the company's revenue reached $1.915 billion, a growth of over 120 times in three years, showing strong momentum.
Ratings and Target Price: MoffettNathanson gave CoreWeave a "Neutral" rating with a target price of $43, lower than the trading price of $51.57 at the time, as analysts believe the company faces significant risks and uncertainties.
9. Globally Recognized Footwear and Apparel Company $Skechers USA(SKX)$
Financials: Although the Q1 2025 financial results have not been announced, Skechers reported a record sales of $2.35 billion in Q3 2024, a year-over-year increase of 16%.
Significant Partnership: Skechers agreed to be acquired by 3G Capital at a price of $63 per share, 30% higher than the company's 15-day volume-weighted average price.
Ratings and Target Price: According to Yahoo Finance, analysts' one-year target price for Skechers is $63.93, indicating a positive market expectation for the company's future performance.
10. Canadian Gold and Copper Mining Company $New Gold(NGD)$
Performance and Development: In Q1 2025, the company achieved revenue of $209.1 million, a year-over-year increase of 8.8%, exceeding analyst expectations by 22%. The company also announced a new mine development plan, and New Gold's stock price reached a 52-week high on May 3, 2025.
Ratings and Target Price: Analysts generally rate New Gold as "Moderate Buy," with an average target price of $3.85
Open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
